FSGS
2
Pipeline Programs
2
Companies
2
Clinical Trials
0
Approved Products
Pipeline by Development Stage
Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
0
1
1
0
Early DiscoveryClinical DevelopmentMarket
Competitive Landscape
2 companies ranked by most advanced pipeline stage
Trial Timeline
Clinical trial activity over time
2021
2022
2023
2024
2025
2026
2027
2028
2029
Colorado TherapeuticsActhar
Apellis PharmaceuticalsAPL2
Clinical Trials (2)
Total enrollment: 285 patients across 2 trials
Use of Acthar in Patients With FSGS That Will be Undergoing Renal Transplantation
Start: Feb 2019Est. completion: Jun 202415 patients
Phase 3Completed
A Sequential Phase 2/3 Study of APL2 in Patients With Focal Segmental Glomerulosclerosis
Start: Dec 2025Est. completion: Dec 2029270 patients
Phase 2/3Not Yet Recruiting
Related Jobs
Patient Analytics Senior Manager
Boston, MA
3w ago
$138K - $206K/yr
Medical Affairs Associate Medical Director - Nephrology
Boston, MA
3w ago
$187K - $281K/yr
Executive Director, Clinical Development Nephrology
Remote
4w ago
$285K - $385K/yr
Senior Director, Market Enablement
Boston, MA
1mo ago
$232K - $348K/yr
Clinical Account Manager (Cherry Hill, NJ)
Remote
1mo ago
$162K - $211K/yr
Market Research Associate Director
Boston, MA
1mo ago
$158K - $237K/yr
Phase Legend
Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available
Key Insights
1 late-stage (Phase 3) programs, potential near-term approvals
2 companies competing in this space
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.